N-(4-chlorophenyl)-3-(3-methoxyphenyl)prop-2-enamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: N-(4-chlorophenyl)-3-(3-methoxyphenyl)prop-2-enamide
• 化学式: C₁₆H₁₄ClNO₂
• 分子量: 287.74
• InChiKey: GPUCMXAMYPELCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
  申请人：Shafer L. Steven

  公开号：US20060128676A1

  公开（公告）日：2006-06-15

  Disclosed herein are compositions of nicotinic agonists, salts, hydrates, solvates or prodrugs thereof and therapeutic agents salts, hydrates, solvates or prodrugs thereof, pharmaceutical compositions thereof and methods of using these compositions and pharmaceutical compositions thereof to treat or prevent disease or pain in a subject. Also disclosed are methods of treating disease or pain or preventing disease or pain in a subject with nicotinic agonists, salts, hydrates, solvates or prodrugs thereof and therapeutic agents, salts, hydrates, solvates or prodrugs thereof.
• Method to Abate Acute Airway Hypersensitivity and Asthma Attacks
  申请人：UTI Limited Partnership

  公开号：US20200215085A1

  公开（公告）日：2020-07-09

  Methods for prevention and treatment of asthma attacks involve the administration of one or more TRPV1 antagonists, one or more LPAr antagonists or preferably a combination of one or more TRPV1 antagonists and one or more LPAr antagonists. TRPV1 antagonists and/or LPAr antagonists or a combination of both inhibit or prevent carotid body activation during an acute asthma attack. TRPV1 antagonists, LPAr antagonists or a combination thereof are useful for preventing or ameliorating the symptoms of asthma attacks. Pharmaceutical compositions for use in treating asthma and more specifically for preventing or treating asthma attacks comprise a combination of a TRPV1 antagonist and an LPAr antagonist. Methods for making medicaments for such treatment are provided. Also provided are kits for treating asthma and for preventing or treating asthma attacks in which a TRPV1 antagonist and an LPAr antagonist are separately formulated for administration at the same time.
• [EN] COMPOSITIONS OF NICOTINIC AGONISTS AND THERAPEUTIC AGENTS AND METHODS FOR TREATING OR PREVENTING DISEASE OR PAIN<br/>[FR] COMPOSITIONS D'AGONISTES NICOTINIQUES ET D'AGENTS THÉRAPEUTIQUES ET MÉTHODES DE TRAITEMENT ET DE PRÉVENTION DES MALADIES OU DES DOULEURS
  申请人：PHARMACOFORE INC

  公开号：WO2006017354A1

  公开（公告）日：2006-02-16

  Disclosed herein are compositions of nicotinic agonists, salts, hydrates, solvates or prodrugs thereof and therapeutic agents salts, hydrates, solvates or prodrugs thereof, pharmaceutical compositions thereof and methods of using these compositions and pharmaceutical compositions thereof to treat or prevent disease or pain in a subject. Also disclosed are methods of treating disease or pain or preventing disease or pain in a subject with nicotinic agonists, salts, hydrates, solvates or prodrugs thereof and therapeutic agents, salts, hydrates, solvates or prodrugs thereof.
• [EN] IDENTIFICATION OF DRUGS THAT INCREASE MUSCLE MASS<br/>[FR] IDENTIFICATION DE MÉDICAMENTS AUGMENTANT LA MASSE MUSCULAIRE
  申请人：UNIV CALIFORNIA

  公开号：WO2017208211A1

  公开（公告）日：2017-12-07

  Compounds identified in a high-throughput screen, and methods involving them, to increase muscle mass and muscle function and to treat muscular dystrophy, in particular limb girdle muscular dystrophy type 2A are disclosed.
• [EN] METHOD TO ABATE ACUTE AIRWAY HYPERSENSITIVITY AND ASTHMA ATTACKS<br/>[FR] PROCÉDÉ POUR RÉDUIRE L'HYPERSENSIBILITÉ AIGUË DES VOIES RESPIRATOIRES ET LES CRISES D'ASTHME
  申请人：UTI LP

  公开号：WO2019014748A1

  公开（公告）日：2019-01-24

  Methods for prevention and treatment of asthma attacks involve the administration of one or more TRPV1 antagonists, one or more LPAr antagonists or preferably a combination of one or more TRPV1 antagonists and one or more LPAr antagonists. TRPV1 antagonists and/or LPAr antagonists or a combination of both inhibit or prevent carotid body activation during an acute asthma attack. TRPV1 antagonists, LPAr antagonists or a combination thereof are useful for preventing or ameliorating the symptoms of asthma attacks. Pharmaceutical compositions for use in treating asthma and more specifically for preventing or treating asthma attacks comprise a combination of a TRPV1 antagonist and an LPAr antagonist. Methods for making medicaments for such treatment are provided. Also provided are kits for treating asthma and for preventing or treating asthma attacks in which a TRPV1 antagonist and an LPAr antagonist are separately formulated for administration at the same time.